Name | Number of supported studies | Average coverage | |
---|---|---|---|
myeloid cell | 4 studies | 20% ± 3% |
Insufficient scRNA-seq data for expression of GPR84 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 98% | 178.96 | 568 / 578 | 86% | 4.32 | 994 / 1155 |
thymus | 98% | 61.16 | 637 / 653 | 54% | 1.29 | 327 / 605 |
breast | 59% | 24.51 | 273 / 459 | 83% | 3.54 | 926 / 1118 |
skin | 67% | 28.03 | 1204 / 1809 | 70% | 3.65 | 332 / 472 |
bladder | 67% | 28.71 | 14 / 21 | 63% | 2.68 | 320 / 504 |
brain | 62% | 39.19 | 1633 / 2642 | 65% | 3.23 | 455 / 705 |
ovary | 46% | 20.59 | 82 / 180 | 80% | 4.21 | 344 / 430 |
uterus | 49% | 18.78 | 83 / 170 | 75% | 2.80 | 344 / 459 |
kidney | 65% | 43.19 | 58 / 89 | 52% | 1.46 | 468 / 901 |
pancreas | 44% | 17.83 | 143 / 328 | 70% | 2.24 | 125 / 178 |
intestine | 52% | 29.68 | 500 / 966 | 62% | 2.17 | 326 / 527 |
stomach | 47% | 35.81 | 170 / 359 | 64% | 2.46 | 184 / 286 |
esophagus | 54% | 23.89 | 776 / 1445 | 54% | 1.31 | 98 / 183 |
adrenal gland | 96% | 78.01 | 248 / 258 | 9% | 0.21 | 21 / 230 |
peripheral blood | 100% | 1224.05 | 925 / 929 | 0% | 0 | 0 / 0 |
spleen | 96% | 265.00 | 232 / 241 | 0% | 0 | 0 / 0 |
prostate | 84% | 49.51 | 205 / 245 | 12% | 0.19 | 58 / 502 |
tonsil | 0% | 0 | 0 / 0 | 87% | 3.75 | 39 / 45 |
lymph node | 0% | 0 | 0 / 0 | 86% | 9.97 | 25 / 29 |
blood vessel | 79% | 66.16 | 1052 / 1335 | 0% | 0 | 0 / 0 |
adipose | 73% | 93.32 | 880 / 1204 | 0% | 0 | 0 / 0 |
liver | 33% | 13.77 | 74 / 226 | 15% | 0.49 | 61 / 406 |
heart | 46% | 25.87 | 392 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 6% | 0.09 | 5 / 80 |
muscle | 4% | 1.10 | 32 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007218 | Biological process | neuropeptide signaling pathway |
GO_0008150 | Biological process | biological_process |
GO_0070821 | Cellular component | tertiary granule membrane |
GO_0043235 | Cellular component | receptor complex |
GO_0035579 | Cellular component | specific granule membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0001604 | Molecular function | urotensin II receptor activity |
Gene name | GPR84 |
Protein name | G-protein coupled receptor 84 (Inflammation-related G-protein coupled receptor EX33) |
Synonyms | EX33 |
Description | FUNCTION: G protein-coupled receptor that responds endogenously to dietary fatty acids or nutrient, specifically medium-chain free fatty acid (FFA) with carbon chain lengths of C9 to C14. Capric acid (C10:0), undecanoic acid (C11:0) and lauric acid (C12:0) are the most potent agonists . In immune cells, functions as a pro-inflammatory receptor via 6-OAU and promotes the expression of pro-inflammatory mediators such as TNFalpha, IL-6 and IL-12B as well as stimulating chemotactic responses through activation of signaling mediators AKT, ERK and NF-kappa-B (By similarity). In addition, triggers increased bacterial adhesion and phagocytosis in macrophages and regulates pro-inflammatory function via enhancing NLRP3 inflammasome activation (By similarity). Plays also an important role in inflammation by modulating neutrophil functions (By similarity). Mechanistically, promotes neutrophil chemotaxis, reactive oxygen species (ROS) production and degranulation via LYN-AKT/ERK pathway (By similarity). To regulate ROS, communicates with the two formyl peptide receptors FPR2 and FPR1 to control the NADPH oxidase activity in neutrophils . . |
Accessions | Q9NQS5 ENST00000267015.4 ENST00000551809.1 |